• Journals Master List
  • DOAJ
  • 数据库logo
  • EuroPub
Ning Jia-xuan, Ye Nan, Wang Guo-qin, Bian Wei-jing, Cheng Hong. Advances of safety of antithrombotic therapy in patients with chronic kidney disease plus atrial fibrillation after percutaneous coronary intervention[J]. Journal of Clinical Nephrology, 2024, 24(9): 772-775. DOI: 10.3969/j.issn.1671-2390.2024.09.009
Citation: Ning Jia-xuan, Ye Nan, Wang Guo-qin, Bian Wei-jing, Cheng Hong. Advances of safety of antithrombotic therapy in patients with chronic kidney disease plus atrial fibrillation after percutaneous coronary intervention[J]. Journal of Clinical Nephrology, 2024, 24(9): 772-775. DOI: 10.3969/j.issn.1671-2390.2024.09.009

Advances of safety of antithrombotic therapy in patients with chronic kidney disease plus atrial fibrillation after percutaneous coronary intervention

Funds: Beijing Municipal Hospital Scientific Research & Cultivation Project (PX2022024)
More Information
  • Corresponding author:

    Cheng Hong, Email:drchengh@163.com

  • Received Date: December 10, 2023
  • Patients of atrial fibrillation (AF) are prone to develop secondary coronary artery disease (CAD) and acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) is required. Anticoagulation and antiplatelet therapy are a gold standard for AF patients with post-PCI. However, there is a great risk of hemorrhage. Renal function affects the occurrence of hemorrhagic events and then shifts a balance of advantages and disadvantages of antithrombotic therapy. The safety of antithrombotic therapy was explored in patients with chronic kidney disease (CKD) complicated with AF post-PCI. The databases of PubMed, Cochrane and EMBASE were searched for cohort research studies of CKD plus AF patients on antithrombotic therapy post-PCI. As compared with those taking vitamin K antagonists, users of direct oral anticoagulants (DOAC) had fewer hemorrhagic events. For CKD plus AF patients post-PCI, the safety of DOAC was higher than those taking vitamin K antagonists. For patients with eGFR >30 mL·min−1·(1.73 m2−1, the progression of CKD had no significant impact on the safety of DOAC.

  • [1]
    Cases A, Gomez P, Broseta JJ, et al. Non-valvular atrial fibrillation in CKD: role of vitamin K antagonists and direct oral anticoagulants: a narrative review[J]. Front Med,2021,8:654620. DOI: 10.3389/fmed.2021.654620.
    [2]
    Hijazi Z, Alexander JH, Li ZK, et al. Apixaban or vitamin K antagonists and aspirin or placebo according to kidney function in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention: insights from the AUGUSTUS trial[J]. Circulation,2021,143(12):1215-1223. DOI: 10.1161/CIRCULATIONAHA.120.051020.
    [3]
    Lee KH, Ou SM, Chu YC, et al. Antithrombotic therapy for chronic kidney disease patients with concomitant atrial fibrillation and coronary artery disease[J]. Front Cardiovasc Med,2021,8:751359. DOI: 10.3389/fcvm.2021.751359.
    [4]
    Magnocavallo M, Bellasi A, Mariani MV, et al. Thromboembolic and bleeding risk in atrial fibrillation patients with chronic kidney disease: role of anticoagulation therapy[J]. J Clin Med,2020,10(1):83. DOI: 10.3390/jcm10010083.
    [5]
    Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation[J]. N Engl J Med,2019,380(16):1509-1524. DOI: 10.1056/NEJMoa1817083
    [6]
    Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study[J]. Lancet,2012,380(9844):807-814. DOI: 10.1016/S0140-6736(12)60572-8.
    [7]
    李明阳, 李文平, 王沛坚. 心房颤动伴慢性肾脏病口服抗凝治疗的研究进展[J]. 山东医药,2022,62(25):104-107.DOI: 10.3969/j.issn.1002-266X.2022.25.026.

    Li MY, Li WP, Wang PJ. Research progress of oral anticoagulation therapy for atrial fibrillation with chronic kidney disease[J]. Shandong Med J,2022,62(25):104-107. DOI: 10.3969/j.issn.1002-266X.2022.25.026.
    [8]
    Kumar S, Lim E, Covic A, et al. Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week[J]. J Am Coll Cardiol,2019,74(17):2204-2215. DOI: 10.1016/j.jacc.2019.08.1031.
    [9]
    Lopes RD, Hong H, Harskamp RE, et al. Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials[J]. JAMA Cardiol,2019,4(8):747-755. DOI: 10.1001/jamacardio.2019.1880.
    [10]
    肖淑娜. 达比加群酯在房颤合并冠心病PCI术后抗凝治疗中的有效性及安全性研究[J]. 实用中西医结合临床,2023,23(4):51-53,56.DOI: 10.13638/j.issn.1671-4040.2023.04.013.

    Xiao SN. Efficacy and safety study of dabigatran ester in anticoagulant treatment of atrial fibrillation complicated with coronary heart disease after PCI[J]. Pra Clin J of Int Tra Chin and West Med,2023,23(4):51-53,56. DOI: 10.13638/j.issn.1671-4040.2023.04.013.
    [11]
    Said S, Hernandez GT. The link between chronic kidney disease and cardiovascular disease[J]. J Nephropathol,2014,3(3):99-104. DOI: 10.12860/jnp.2014.19.
    [12]
    Lau YC, Proietti M, Guiducci E, et al. Atrial fibrillation and thromboembolism in patients with chronic kidney disease[J]. J Am Coll Cardiol,2016,68(13):1452-1464. DOI: 10.1016/j.jacc.2016.06.057.
    [13]
    Aursulesei V, Costache II. Anticoagulation in chronic kidney disease: from guidelines to clinical practice[J]. Clin Cardiol,2019,42(8):774-782. DOI: 10.1002/clc.23196.
    [14]
    Bos MJ, Koudstaal PJ, Hofman A, et al. Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam Study[J]. Stroke,2007,38(12):3127-3132. DOI: 10.1161/STROKEAHA.107.489807.
    [15]
    Angiolillo DJ, Galli M, Collet JP, et al. Antiplatelet therapy after percutaneous coronary intervention[J]. EuroIntervention,2022,17(17):e1371-e1396. DOI: 10.4244/EIJ-D-21-00904.
    [16]
    Sharma R, Kumar P, Prashanth SP, et al. Dual antiplatelet therapy in coronary artery disease[J]. Cardiol Ther,2020,9(2):349-361. DOI: 10.1007/s40119-020-00197-0.
    [17]
    吴鸿谊, 钱菊英. 急性冠脉综合征的抗栓治疗[J]. 中国实用内科杂志,2021,41(8):657-660.DOI: 10.19538/j.nk2021080103.

    Wu HY, Qian JY. Antithrombotic therapy for acute coronary syndrome[J]. Chin J Pract Intern. Med,2021,41(8):657-660. DOI: 10.19538/j.nk2021080103.
    [18]
    Sjögren V, Byström B, Renlund H, et al. Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: a retrospective register study[J/OL]. PLoS One,2017,12(7):e0181000. DOI: 10.1371/journal.pone.0181000.
    [19]
    中华医学会心血管病学分会, 中国老年学学会心脑血管病专业委员会. 华法林抗凝治疗的中国专家共识[J]. 中华内科杂志,2013,52(1):76-82.DOI: 10.3760/cma.j.issn.0578-1426.2013.01.027.

    Chinese Society of Cardiolgy of Chinese Medical Association, Committee of Cardio-cerebral-Vascular of GSC. Chinese expert consensus on anticoagulant therapy with warfarin[J]. Chin J Intern Med,2013,52(1):76-82. DOI: 10.3760/cma.j.issn.0578-1426.2013.01.027.
    [20]
    Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med,2009,361(12):1139-1151. DOI: 10.1056/NEJMoa0905561.
    [21]
    Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med,2011,365(11):981-992. DOI: 10.1056/NEJMoa1107039.
    [22]
    Ambe K, Akita A, Wei J, et al. Comparison of efficacy and safety of direct oral anticoagulants and warfarin between patients in Asian and non-Asian regions: a systematic review and meta-regression analysis[J]. Clin Pharmacol Ther,2023,113(6):1240-1250. DOI: 10.1002/cpt.2881.
    [23]
    中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 冠心病合并心房颤动患者抗栓管理中国专家共识[J]. 中华心血管病杂志,2020,48(7):552-564.DOI: 10.3760/cma.j.cn112148-20200328-00257.

    Chinese Society of Cardiolgy of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. Antithrombotic management of patients with atrial fibrillation and coronary artery disease: expert consensus document of Chinese Society of Cardiology[J]. Chin J Cardiol,2020,48(7):552-564. DOI: 10.3760/cma.j.cn112148-20200328-00257.
    [24]
    Hohnloser SH, Steg PG, Oldgren J, et al. Renal function and outcomes with dabigatran dual antithrombotic therapy in atrial fibrillation patients after PCI[J]. JACC Cardiovasc Interv,2019,12(16):1553-1561. DOI: 10.1016/j.jcin.2019.05.050.
    [25]
    Lopes RD, Vora AN, Liaw D, et al. An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial[J]. Am Heart J,2018,200:17-23. DOI: 10.1016/j.ahj.2018.03.001.
    [26]
    张新超. 老年房颤合并ACS或PCI患者的抗栓治疗[J]. 中国急救医学,2021,41(11):921-926.DOI: 10.3969/j.issn.1002-1949.2021.11.001.

    Zhang XC. Antithrombotic therapy in elderly patients with atrial fibrillation complicated with ACS or PCI[J]. Chin J Crit Care Nov,2021,41(11):921-926. DOI: 10.3969/j.issn.1002-1949.2021.11.001.

Catalog

    Article views (55) PDF downloads (12) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return